Germany respiratory drug market was valued more than $3.0 billion in 2018 and is anticipated to grow at a substantial rate of 7.2% during the forecast period. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors augmenting the growth of the respiratory drug market in the country. Moreover, the presence of market players in the country is also influencing the market growth of the country. For instance, Ingelheim-based Boehringer Ingelheim International GmbH collaborated with Weill Cornell Medicine in February 2017. The aim of the collaboration is to find new treatment approaches for chronic pulmonary diseases. The three-year collaboration aimed to develop novel treatments that could stop and deteriorate the progression of COPD.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/germany-respiratory-drug-market
The Germany respiratory drug market is segmented on the basis of the route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, injectable, and inhalable. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the high prevalence of asthma in the country. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/germany-respiratory-drug-market
Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing respiratory drugs to cater to a wide range of customers within and outside the region. The major players of the Germany respiratory drug market include Boehringer Ingelheim International GmbH, AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, F. Hoffmann-La Roche Ltd., and Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.
Market Segmentation
Germany Respiratory Drug Market by Route of Administration
- Oral
- Injectable
- Inhalable
Germany Respiratory Drug Market by Application
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
Germany Respiratory Drug Market by End-User
- Homecare
- Hospitals and Clinics
Company Profiles
- Air Liquide S.A.
- Aradigm Corp.
- AstraZeneca PLC
- Baxter International Inc.
- Boehringer Ingelheim International GmbH
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC
- Merck & Co.
- Novartis AG
- Omron Healthcare Inc.
- Pfizer Inc.
- Pulmatrix Inc.
- ResMed Corp.
- Savara, Inc.
- Sunovion Pharmaceuticals
- Takeda Pharmaceutical Company Ltd.
- Teva Pharmaceuticals Industries Ltd.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
